Mariola Jasikowska
Research Subjects
Mariola Jasikowska has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Bartłomiej Kamiński
Department of Otolaryngology, Maria Skłodowska-Curie District Hospital, 26-110 Skarżysko-Kamienna, Poland
1 shared publication - Cezary Pałczyński
Collegium Medicum, Jan Kochanowski University, 25-369 Kielce, Poland
1 shared publication - Dominika Ochab
Collegium Medicum, Jan Kochanowski University, 25-369 Kielce, Poland
1 shared publication - Piotr Łacwik
Collegium Medicum, Jan Kochanowski University, 25-369 Kielce, Poland
1 shared publication - Stanisław Flaga
AGH University of Krakow, Faculty of Mechanical Engineering and Robotics, 30-059 Kraków, Poland
1 shared publication
Latest Publications
- Open Access
- 4 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5228
Comparison of Dupilumab and Revision Endoscopic Sinus Surgery for Recurrent Chronic Rhinosinusitis with Nasal Polyps: A Retrospective Cohort Study
Background: Despite growing evidence supporting the efficacy of dupilumab in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), studies directly comparing biologic therapy with revision endoscopic sinus surgery remain limited. This study aimed to compare the effectiveness of dupilumab and revision endoscopic sinus surgery (ESS) in patients with recurrent CRSwNP. Methods: A retrospective cohort study was conducted in 50 patients with CRSwNP who had previously undergone at least two endoscopic sinus surgeries. Twenty-three patients received dupilumab, while twenty-seven underwent revision surgery. Changes in Nasal Polyp Score (NPS), quality of life assessed using the Sino-Nasal Outcome Test-22 (SNOT-22), and olfactory function evaluated with the Sniffin’ Sticks test were analyzed. Final clinical outcomes and the proportion of patients achieving very good disease control were also assessed. Results: Both treatment modalities improved disease control. However, dupilumab was associated with significantly greater reductions in NPS (median [IQR]: −6.00 [−6.00 to −5.00] vs. −4.00 [−6.00 to −3.00]; p = 0.012), larger improvements in SNOT-22 scores (−59.39 ± 12.14 vs. −21.37 ± 20.15; p < 0.001), and better recovery of olfactory function (+4.65 ± 2.79 vs. +2.19 ± 2.08; p = 0.001) compared with revision surgery. Analysis of final outcomes also favored dupilumab, with lower NPS scores (median [IQR]: 0.00 [0.00–1.00] vs. 1.00 [0.00–2.50]; p = 0.023), and better olfactory function (7.65 ± 3.11 vs. 4.78 ± 2.34; p < 0.001). Very good symptom control (SNOT-22 < 20) was achieved by 82.6% of patients treated with dupilumab compared with 7.4% of those undergoing revision surgery. Conclusions: Both revision surgery and dupilumab improved disease control in patients with CRSwNP. In this cohort, dupilumab was associated with greater reductions in disease severity, superior quality-of-life outcomes, and better olfactory function than revision endoscopic sinus surgery.
- 4 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5228
Open AccessComparison of Dupilumab and Revision Endoscopic Sinus Surgery for Recurrent Chronic Rhinosinusitis with Nasal Polyps: A Retrospective Cohort Study
Background: Despite growing evidence supporting the efficacy of dupilumab in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), studies directly comparing biologic therapy with revision endoscopic sinus surgery remain limited. This study aimed to compare the effectiveness of dupilumab and revision endoscopic sinus surgery (ESS) in patients with recurrent CRSwNP. Methods: A retrospective cohort study was conducted in 50 patients with CRSwNP who had previously undergone at least two endoscopic sinus surgeries. Twenty-three patients received dupilumab, while twenty-seven underwent revision surgery. Changes in Nasal Polyp Score (NPS), quality of life assessed using the Sino-Nasal Outcome Test-22 (SNOT-22), and olfactory function evaluated with the Sniffin’ Sticks test were analyzed. Final clinical outcomes and the proportion of patients achieving very good disease control were also assessed. Results: Both treatment modalities improved disease control. However, dupilumab was associated with significantly greater reductions in NPS (median [IQR]: −6.00 [−6.00 to −5.00] vs. −4.00 [−6.00 to −3.00]; p = 0.012), larger improvements in SNOT-22 scores (−59.39 ± 12.14 vs. −21.37 ± 20.15; p < 0.001), and better recovery of olfactory function (+4.65 ± 2.79 vs. +2.19 ± 2.08; p = 0.001) compared with revision surgery. Analysis of final outcomes also favored dupilumab, with lower NPS scores (median [IQR]: 0.00 [0.00–1.00] vs. 1.00 [0.00–2.50]; p = 0.023), and better olfactory function (7.65 ± 3.11 vs. 4.78 ± 2.34; p < 0.001). Very good symptom control (SNOT-22 < 20) was achieved by 82.6% of patients treated with dupilumab compared with 7.4% of those undergoing revision surgery. Conclusions: Both revision surgery and dupilumab improved disease control in patients with CRSwNP. In this cohort, dupilumab was associated with greater reductions in disease severity, superior quality-of-life outcomes, and better olfactory function than revision endoscopic sinus surgery.